FR2364906A1 - Cimetidine A used as histamine H-2 receptor blocker - is a crystallographically pure polymorphic form of N-methyl-(N')-cyano-(N'')-methyl-imidazolyl methylthio-ethyl-guanidine - Google Patents

Cimetidine A used as histamine H-2 receptor blocker - is a crystallographically pure polymorphic form of N-methyl-(N')-cyano-(N'')-methyl-imidazolyl methylthio-ethyl-guanidine

Info

Publication number
FR2364906A1
FR2364906A1 FR7727887A FR7727887A FR2364906A1 FR 2364906 A1 FR2364906 A1 FR 2364906A1 FR 7727887 A FR7727887 A FR 7727887A FR 7727887 A FR7727887 A FR 7727887A FR 2364906 A1 FR2364906 A1 FR 2364906A1
Authority
FR
France
Prior art keywords
methyl
polymorphic form
guanidine
cyano
cimetidine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
FR7727887A
Other languages
French (fr)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Smith Kline and French Laboratories Ltd
Original Assignee
Smith Kline and French Laboratories Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB3906576A external-priority patent/GB1543238A/en
Application filed by Smith Kline and French Laboratories Ltd filed Critical Smith Kline and French Laboratories Ltd
Publication of FR2364906A1 publication Critical patent/FR2364906A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

A practically crystallographically pure polymorphic form of cimetidin N-methyl-N'-cyano-N"-(2-((5-methyl-4-imidazolyl)-methylthio)ethy- l)guanidine , (as cimetidin A). (I), has an infrared spectrum (1% on KBr disc) having broad, pronounced (high) peaks at 1400 and 1395cm-1, a narrow pronounced peak at 1205 cm-1 and a narrow peak of av. height at 1155cm-1 and no peak at 1180 cm-1. Practically crystallographically pure indicates that (I) contains 5(3)%, of any other polymorphic form. (I) is administered in unit doses of 50-750mg (pref. 200-600mg), 1-6 times daily to give a pref. daily dosage of 500-1500mg. (I) is usually administered orally but may also be given parenterally or topically.
FR7727887A 1976-09-21 1977-09-15 Cimetidine A used as histamine H-2 receptor blocker - is a crystallographically pure polymorphic form of N-methyl-(N')-cyano-(N'')-methyl-imidazolyl methylthio-ethyl-guanidine Withdrawn FR2364906A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB3906576A GB1543238A (en) 1976-09-21 1976-09-21 Polymorph of cimetidine
GB271677 1977-01-24

Publications (1)

Publication Number Publication Date
FR2364906A1 true FR2364906A1 (en) 1978-04-14

Family

ID=26237687

Family Applications (1)

Application Number Title Priority Date Filing Date
FR7727887A Withdrawn FR2364906A1 (en) 1976-09-21 1977-09-15 Cimetidine A used as histamine H-2 receptor blocker - is a crystallographically pure polymorphic form of N-methyl-(N')-cyano-(N'')-methyl-imidazolyl methylthio-ethyl-guanidine

Country Status (10)

Country Link
JP (1) JPS5340771A (en)
AU (1) AU510629B2 (en)
BE (1) BE858432A (en)
CA (1) CA1096387A (en)
DE (1) DE2742531A1 (en)
FR (1) FR2364906A1 (en)
IE (1) IE45873B1 (en)
IL (1) IL52784A (en)
LU (1) LU78142A1 (en)
NZ (1) NZ184893A (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS56104868A (en) * 1980-01-24 1981-08-20 Fujimoto Seiyaku Kk Conversion between polymorphous crystals of cimetidine
JPS56164122A (en) * 1980-05-21 1981-12-17 Fujimoto Seiyaku Kk Drug composition comprising cimetidine as main agent
HU185636B (en) * 1981-06-26 1985-03-28 Richter Gedeon Vegyeszet Process for preparing new cimetidine-hydrate /cimetidine-h/
HU185457B (en) * 1981-09-25 1985-02-28 Richter Gedeon Vegyeszet Process for preparating cimetidine-z
JPS5888366A (en) * 1981-11-19 1983-05-26 Fujimoto Seiyaku Kk Preparation of guanidine derivative
JPS59128375A (en) * 1983-01-10 1984-07-24 Tokawa Tetsuo Preparation of imidazole compound
JPS59130274A (en) * 1983-01-14 1984-07-26 Tokawa Tetsuo Preparation of imidazole compound
JPS59130273A (en) * 1983-01-14 1984-07-26 Tokawa Tetsuo Preparation of imidazole compound
HU196184B (en) * 1986-09-11 1988-10-28 Richter Gedeon Vegyeszet Process for producing cimetidine-a modification

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL7510334A (en) * 1974-09-02 1976-03-04 Smith Kline French Lab PROCESS FOR PREPARING GUANIDINE COMPOUNDS.
NL7510344A (en) * 1974-09-02 1976-03-04 Smith Kline French Lab PROCEDURE FOR PREPARING PHARMACOLOGICALLY ACTIVE COMPOUNDS.
FR2321490A1 (en) * 1975-08-20 1977-03-18 Smithkline Corp PROCESS FOR THE PREPARATION OF 4- (HYDROXYMETHYL) IMIDAZOLES

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1397436A (en) * 1972-09-05 1975-06-11 Smith Kline French Lab Heterocyclic n-cyanoguinidines

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL7510334A (en) * 1974-09-02 1976-03-04 Smith Kline French Lab PROCESS FOR PREPARING GUANIDINE COMPOUNDS.
NL7510344A (en) * 1974-09-02 1976-03-04 Smith Kline French Lab PROCEDURE FOR PREPARING PHARMACOLOGICALLY ACTIVE COMPOUNDS.
FR2321490A1 (en) * 1975-08-20 1977-03-18 Smithkline Corp PROCESS FOR THE PREPARATION OF 4- (HYDROXYMETHYL) IMIDAZOLES

Also Published As

Publication number Publication date
NZ184893A (en) 1980-11-28
BE858432A (en) 1978-03-06
DE2742531A1 (en) 1978-03-23
JPS5340771A (en) 1978-04-13
IL52784A (en) 1980-09-16
IE45873B1 (en) 1982-12-15
IE45873L (en) 1978-07-24
IL52784A0 (en) 1977-10-31
LU78142A1 (en) 1978-01-17
JPS6222967B2 (en) 1987-05-20
CA1096387A (en) 1981-02-24
AU510629B2 (en) 1980-07-03
AU2879277A (en) 1979-03-22

Similar Documents

Publication Publication Date Title
ES8801968A1 (en) A process for forming nitrided silicon dioxide layers for semiconductor integrated circuits.
FR2364906A1 (en) Cimetidine A used as histamine H-2 receptor blocker - is a crystallographically pure polymorphic form of N-methyl-(N')-cyano-(N'')-methyl-imidazolyl methylthio-ethyl-guanidine
JPS5234671A (en) Semiconductor integrated circuit
JPS52154528A (en) Remedy for glaucoma
JPS5380985A (en) Semiconductor device
HK43996A (en) Superconducting bi-sr-ca-cu oxide compositions and process for manufacture
JPS52116846A (en) Controller for convertor
JPS5240082A (en) Resistor element and process for production of same
Wang General computer simulation formulae of low pressure chemical vapor deposition.
JPS5232263A (en) Semiconductor manufacturing process
JPS5386552A (en) Piezoelectric oscillator
JPS5216697A (en) Method of manufacturing mica sheets or tapes
JPS5362987A (en) Production of mos type semiconductor device
FR2450499A1 (en) PROCESS FOR PREPARING, ON A SUBSTRATE, POLYMERISATE DIELECTRIC LAYERS OBTAINED BY DISCHARGE DISCHARGE, AND USE OF SUCH LAYERS AS A SUBSTRATE
JPS5283558A (en) Novel allantoin-acetylsalycilic acid-aluminum molecular compound and m ethod of making same
JPS5640669A (en) Imidazole derivative and its preparation
EP0164658A3 (en) Ranitidine derivative useful in the treatment of ulcer
JPS5278301A (en) Channel selection equipment
JPS51148388A (en) Semiconductor device including mis type capacitive element
JPS526867A (en) Speed changer
JPS52144982A (en) Semiconductor device
JPS521499A (en) Thick film capacitor
JPS545407A (en) Fast feed driving mechanism of tape recorders or others
HUT57052A (en) Process for producing composition containing plant-extract
JPS5214996A (en) Method for halting polishing work

Legal Events

Date Code Title Description
ST Notification of lapse